Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Brodalumab · Siliq, SILIQ

Monoclonal antibody · Antagonist of IL-17RA · developed by Valeant Luxembourg

Approved FDA, Feb 2017

BHC Developer

1 Registered trials

What is Brodalumab?

Brodalumab is a human monoclonal IgG2 antibody that binds IL-17RA and blocks its interactions with IL-17 family cytokines, inhibiting IL-17-induced pro-inflammatory responses.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Siliq, SILIQ, AMG-827, KHK-4827
Drug type: Monoclonal antibody
Targets: IL-17RA
Mechanism: Antagonist of IL-17RA
Pathways: IL-17 signaling, pro-inflammatory cytokine release
Therapy area: Oncology
Developer: Valeant Luxembourg (BHC)
FDA status: Approved as Siliq (February 15, 2017), BLA761032 · FDA label
UNII: 6ZA31Y954Z

✅ FDA-approved uses

Moderate to severe plaque psoriasis

From the indications section of the FDA label (version of May 28, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06673329	Phase 1	Breast Cancer	Recruiting	BHC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Brain TumorBreast CancerColon CancerEsophageal CancerGynecologic CancerHead and Neck CancerKidney CancerLiver CancerLung CancerOral CancerPancreatic CancerRectal CancerSkin CancerStomach Cancer

More from Valeant Luxembourg

Adapalene / Benzoyl Peroxide / Clindamycin FDA approved Bupropion FDA approved Halobetasol Propionate And Tazarotene FDA approved IDP-118 FDA approved IDP-126 FDA approved Lifitegrast FDA approved Perfluorohexyloctane FDA approved Plecanatide FDA approved Rifaximin FDA approved Timolol FDA approved BL1107 Phase 2 BL1332 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHC page.

Follow BHC, the company behind Brodalumab

See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z